Tyrosine kinase receptors as attractive targets of cancer therapy

Critical Reviews in Oncology/Hematology

Volumn 50, Issue 1, 2004, Pages 23-38

  Bennasroune, Amar ^a   Gardin, Anne ^a,b   Aunis, Dominique ^a   Crémel, Gérard ^a   Hubert, Pierre ^a  

^a INSERM   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Oncology; Receptors; Signaling; Therapy; Tyrosine protein kinase

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALEMTUZUMAB; ANILINOQUINAZOLINE; ANTIBODY; ANTINEOPLASTIC AGENT; CEP 2563; CETUXIMAB; CISPLATIN; CLATHRIN; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GROWTH FACTOR; IMATINIB; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR; PHOSPHOTYROSINE; PROTEIN SH2; QUINAZOLINE DERIVATIVE; RECEPTOR ANTIBODY; RITUXIMAB; SEMAXANIB; SURAMIN; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; BINDING SITE; CANCER THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CLINICAL TRIAL; DEFENSE MECHANISM; DIMERIZATION; DRUG DESIGN; DRUG TARGETING; DRUG THERAPY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME STRUCTURE; HUMAN; LIGAND BINDING; MEDIATOR; MOLECULE; MUTATION; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRYPANOSOMIASIS; TUMOR CELL;

DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; LIGANDS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 3042807464     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.08.004     Document Type: Review

References (161)

1. Sawyers C.L. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12:2002;111-115.
2. Busch H. Onc genes and other new targets for cancer chemotherapy. J. Cancer Res. Clin. Oncol. 107:1984;1-14.
3. Levitzki A. Signal-transduction therapy. A novel approach to disease management. Eur. J. Biochem. 226:1994;1-13.
4. Huber B.E. Therapeutic opportunities involving cellular oncogenes: novel approaches fostered by biotechnology. FASEB J. 3:1989;5-13.
5. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
6. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem 1988;57:443-78.
7. Cantley L.C., Auger K.R., Carpenter C.et al. Oncogenes and signal transduction. Cell. 64:1991;281-302.
8. Walsh T.P., Grant G.H. Computer modelling of the receptor-binding domains of VEGF and PIGF. Protein Eng. 10:1997;389-398.
9. Workman P., Kaye S.B. Translating basic cancer research into new cancer therapeutics. Trends Mol. Med. 8(4):2002;S1-S9.
10. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
11. Cohen P. Protein kinases - the major drug targets of the twenty-first century. Nat. Rev. Drug Discov. 1:2002;309-315.
12. Varmus H., Bishop J.M. Biochemical mechanisms of oncogene activity: proteins encoded by oncogenes. Introduction. Cancer Surv. 5:1986;153-158.
13. Downward J., Yarden Y., Mayes E.et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:1984;521-527.
14. Ullrich A., Coussens L., Hayflick J.S.et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418-425.
15. Slamon D.J., Godolphin W., Jones L.A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
16. Gorre M.E., Mohammed M., Ellwood K.et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
17. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 103:2000;211-225.
18. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365.
19. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene. 19:2000;5548-5557.
20. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
21. Fantl W.J., Johnson D.E., Williams L.T. Signalling by receptor tyrosine kinases. Annu. Rev. Biochem. 62:1993;453-481.
22. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:2000;3159-3167.
23. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:2001;127-137.
24. de Bono J.S., Rowinsky E.K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8:2002;S19-S26.
25. Heldin C.H., Ostman A., Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta. 1378:1998;F79-F113.
26. Marino-Buslje C., Martin-Martinez M., Mizuguchi K., Siddle K., Blundell T.L. The insulin receptor: from protein sequence to structure. Biochem. Soc. Trans. 27:1999;715-726.
27. De Meyts P., Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 1:2002;769-783.
28. Gerwins P., Skoldenberg E., Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit. Rev. Oncol. Hematol. 34:2000;185-194.
29. Taylor M.L., Metcalfe D.D. Kit signal transduction. Hematol. Oncol. Clin. North Am. 14:2000;517-535.
30. Longati P., Comoglio P.M., Bardelli A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr. Drug Targets. 2:2001;41-55.
31. Matsumoto T., Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE. 2001:2001;RE-21.
32. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 169:2001;107-114.
33. Santoro M., Melillo R.M., Carlomagno F., Fusco A., Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann. N. Y. Acad. Sci. 963:2002;116-121.
34. Manie S., Santoro M., Fusco A., Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 17:2001;580-589.
35. Nakamoto M., Bergemann A.D. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc. Res. Tech. 59:2002;58-67.
36. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell. 80:1995;213-223.
37. Weiss A., Schlessinger J. Switching signals on or off by receptor dimerization. Cell. 94:1998;277-280.
38. Brennan P.J., Kumagai T., Berezov A., Murali R., Greene M.I., Kumogai T. HER2/neu: mechanisms of dimerization/oligomerization. Oncogene. 19:2000;6093-6101.
39. Jiang G., Hunter T. Receptor signaling: when dimerization is not enough. Curr. Biol. 9:1999;R568-R571.
40. Bargmann C.I., Weinberg R.A. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J. 7:1988;2043-2052.
41. Weiner D.B., Liu J., Cohen J.A., Williams W.V., Greene M.I. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature. 339:1989;230-231.
42. Burke C.L., Lemmon M.A., Coren B.A., Engelman D.M., Stern D.F. Dimerization of the p185(neu) transmembrane domain is necessary but not sufficient for transformation. Oncogene. 14:1997;687-696.
43. Bell C.A., Tynan J.A., Hart K.C., Meyer A.N., Robertson S.C., Donoghue D.J. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol. Biol. Cell. 11:2000;3589-3599.
44. Hubbard S.R. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. 71:1999;343-358.
45. Hubbard S.R., Till J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69:2000;373-398.
46. Hubbard S.R. Theme and variations: juxtamembrane regulation of receptor protein kinases. Mol. Cell. 8:2001;481-482.
47. Werten P.J., Remigy H.W., de Groot B.L.et al. Progress in the analysis of membrane protein structure and function. FEBS Lett. 529:2002;65-72.
48. Ogiso H., Ishitani R., Nureki O.et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:2002;775-787.
49. Garrett T.P., McKern N.M., Lou M.et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 110:2002;763-773.
50. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 297:2002;1330-1333.
51. Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature. 401:1999;184-188.
52. Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D., Brady R.L. Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Structure (Camb.). 9:2001;1191-1199.
53. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 91:1997;695-704.
54. Himanen J.P., Rajashankar K.R., Lackmann M., Cowan C.A., Henkemeyer M., Nikolov D.B. Crystal structure of an Eph receptor-ephrin complex. Nature. 414:2001;933-938.
55. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754.
56. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16:1997;5572-5581.
57. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
58. Cho H., Mason K., Ramyar K.et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:2003;756-760.
59. Kolibaba K.S., Druker B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta. 1333:1997;F217-F248.
60. Porter A.C., Vaillancourt R.R. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene. 17:1998;1343-1352.
61. Pawson T., Scott J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science. 278:1997;2075-2080.
62. Zong C.S., Poon B., Chen J., Wang L.H. Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros. J. Virol. 67:1993;6453-6462.
63. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur. J. Cancer. 37(4):2001;S3-S8.
64. Klapper L.N., Kirschbaum M.H., Sela M., Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77:2000;25-79.
65. Wells A., Marti U. Signalling shortcuts: cell-surface receptors in the nucleus. Nat. Rev. Mol. Cell Biol. 3:2002;697-702.
66. Khosravi-Far R., Der C.J. The Ras signal transduction pathway. Cancer Metastasis Rev. 13:1994;67-89.
67. Palmer B.D., Rewcastle G.W., Thompson A.M.et al. Tyrosine kinase inhibitors. Part 4. Structure-activity relationships among N- and 3-substituted 2,2′-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases. J. Med. Chem. 38:1995;58-67.
68. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657.
69. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer. 38:2002;S3-S10.
70. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:2002;489-501.
71. Hubbard S.R., Mohammadi M., Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J. Biol. Chem. 273:1998;11987-11990.
72. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 80:1995;225-236.
73. Ostman A., Bohmer F.D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 11:2001;258-266.
74. Waterman H., Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490:2001;142-152.
75. Shtiegman K., Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin. Cancer Biol. 13:2003;29-40.
76. Katz M., Shtiegman K., Tal-Or P.et al. Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic. 3:2002;740-751.
77. Citri A., Alroy I., Lavi S.et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21:2002;2407-2417.
78. Masters J.R. Human cancer cell lines: fact and fantasy. Nat. Rev. Mol. Cell Biol. 1:2000;233-236.
79. Brandt R., Wong A.M., Hynes N.E. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene. 20:2001;5459-5465.
80. Lewandoski M. Conditional control of gene expression in the mouse. Nat. Rev. Genet. 2:2001;743-755.
81. Klausner R.D. Studying cancer in the mouse. Oncogene. 18:1999;5249-5252.
82. DePinho R.A., Jacks T. The laboratory mouse in cancer research. Semin. Cancer Biol. 11:2001;175-176.
83. Hann B., Balmain A. Building 'validated' mouse models of human cancer. Curr. Opin. Cell Biol. 13:2001;778-784.
84. Herzig M., Christofori G. Recent advances in cancer research: mouse models of tumorigenesis. Biochim. Biophys. Acta. 1602:2002;97-113.
85. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 54:1988;105-115.
86. Rosenberg M.P., Bortner D. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metastasis Rev. 17:1998;295-299.
87. Bouchard L., Lamarre L., Tremblay P.J., Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell. 57:1989;931-936.
88. Muller W.J., Arteaga C.L., Muthuswamy S.K. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol. Cell. Biol. 16:1996;5726-5736.
89. Lenferink A.E., Simpson J.F., Shawver L.K., Coffey R.J., Forbes J.T., Arteaga C.L. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9609-9614.
90. Weinstein E.J., Kitsberg D.I., Leder P. A mouse model for breast cancer induced by amplification and overexpression of the neu promoter and transgene. Mol. Med. 6:2000;4-16.
91. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10578-10582.
92. Guy C.T., Cardiff R.D., Muller W.J. Activated neu induces rapid tumor progression. J. Biol. Chem. 271:1996;7673-7678.
93. DiGiovanna M.P., Lerman M.A., Coffey R.J., Muller W.J., Cardiff R.D., Stern D.F. Active signaling by Neu in transgenic mice. Oncogene. 17:1998;1877-1884.
94. Jeffers M., Fiscella M., Webb C.P., Anver M., Koochekpour S., Vande Woude G.F. The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;14417-14422.
95. Santoro M., Chiappetta G., Cerrato A.et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene. 12:1996;1821-1826.
96. Michiels F.M., Chappuis S., Caillou B.et al. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3330-3335.
97. Larcher F., Murillas R., Bolontrade M., Conti C.J., Jorcano J.L. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis. Oncogene. 17:1998;303-311.
98. Sweetser D.A., Froelick G.J., Matsumoto A.M.et al. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice. Oncogene. 18:1999;877-886.
99. Xie W., Chow L.T., Paterson A.J., Chin E., Kudlow J.E. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene. 18:1999;3593-3607.
100. Kiguchi K., Bol D., Carbajal S.et al. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene. 19:2000;4243-4254.
101. Hayes C., Kelly D., Murayama S., Komiyama A., Suzuki K., Popko B. Expression of the neu oncogene under the transcriptional control of the myelin basic protein gene in transgenic mice: generation of transformed glial cells. J. Neurosci. Res. 31:1992;175-187.
102. Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Invest. 109:2002;69-78.
103. Houseman B.T., Huh J.H., Kron S.J., Mrksich M. Peptide chips for the quantitative evaluation of protein kinase activity. Nat. Biotechnol. 20:2002;270-274.
104. Zaniboni A. Suramin: the discovery of an old anticancer drug. Med. Oncol. Tumor Pharmacother. 7:1990;287-290.
105. Kaur M., Reed E., Sartor O., Dahut W., Figg W.D. Suramin's development: what did we learn? Invest. New Drugs. 20:2002;209-219.
106. Sebti S.M., Hamilton A.D. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene. 19:2000;6566-6573.
107. Blaskovich M.A., Lin Q., Delarue F.L.et al. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat. Biotechnol. 18:2000;1065-1070.
108. Glennie M.J., Johnson P.W. Clinical trials of antibody therapy. Immunol. Today. 21:2000;403-410.
109. Sarup J.C., Johnson R.M., King K.L. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:1991;72-82.
110. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., Hynes N.E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell Biol. 20:2000;3210-3223.
111. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:2001;4744-4749.
112. Masui H., Kawamoto T., Sato J.D., Wolf B., Sato G., Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44:1984;1002-1007.
113. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1:1995;1311-1318.
114. Baselga J., Norton L., Masui H.et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 85:1993;1327-1333.
115. Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur. J. Cancer. 37(Suppl 4):2001;S16-S22.
116. Petit A.M., Rak J., Hung M.C.et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151:1997;1523-1530.
117. Liu B., Fang M., Schmidt M., Lu Y., Mendelsohn J., Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br. J. Cancer. 82:2000;1991-1999.
118. Shin D.M., Donato N.J., Perez-Soler R.et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7:2001;1204-1213.
119. Yang X.D., Jia X.C., Corvalan J.R., Wang P., Davis C.G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38:2001;17-23.
120. Park B.W., Zhang H.T., Wu C.et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18:2000;194-198.
121. Berezov A., Zhang H.T., Greene M.I., Murali R. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J. Med. Chem. 44:2001;2565-2574.
122. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer. 1:2001;118-129.
123. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer. 2:2002;750-763.
124. Garrett M.D., Workman P. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer. 35:1999;2010-2030.
125. Druker B.J., Lydon N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105:2000;3-7.
126. Buchdunger E., Zimmermann J., Mett H.et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
127. Morin M.J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene. 19:2000;6574-6583.
128. Wang W.L., Healy M.E., Sattler M.et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI-571. Oncogene. 19:2000;3521-3528.
129. Demetri G.D., von Mehren M., Blanke C.D.et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.
130. Hernandez-Boluda J.C., Cervantes F. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. Drugs Today (Barc.). 38:2002;601-613.
131. Denny W.A. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmacol. 56:2001;51-56.
132. Ciardiello F., Caputo R., Bianco R.et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063.
133. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29:2002;15-18.
134. Laird A.D., Vajkoczy P., Shawver L.K.et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60:2000;4152-4160.
135. Zutshi R., Brickner M., Chmielewski J. Inhibiting the assembly of protein-protein interfaces. Curr. Opin. Chem. Biol. 2:1998;62-66.
136. Chardin P., Cussac D., Maignan S., Ducruix A. The Grb2 adaptor. FEBS Lett. 369:1995;47-51.
137. Garbay C., Liu W.Q., Vidal M., Roques B.P. Inhibitors of Ras signal transduction as antitumor agents. Biochem. Pharmacol. 60:2000;1165-1169.
138. Kim H., Muller W.J. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp. Cell Res. 253:1999;78-87.
139. Cussac D., Vidal M., Leprince C. A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity. FASEB J. 13:1999;31-38.
140. Liu W.Q., Vidal M., Gresh N., Roques B.P., Garbay C. Small peptides containing phosphotyrosine and adjacent alphaMe-phosphotyrosine or its mimetics as highly potent inhibitors of Grb2 SH2 domain. J. Med. Chem. 42:1999;3737-3741.
141. Cochran A.G. Antagonists of protein-protein interactions. Chem. Biol. 7:2000;R85-R94.
142. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 110:2002;669-672.
143. Berezov A., Chen J., Liu Q., Zhang H.T., Greene M.I., Murali R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 277:2002;28330-28339.
144. Lofts F.J., Hurst H.C., Sternberg M.J., Gullick W.J. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene. 8:1993;2813-2820.
145. Qian X., O'Rourke D.M., Zhao H., Greene M.I. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene. 13:1996;2149-2157.
146. Cohen P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 3:1999;459-465.
147. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumor biology: Herceptin acts as an anti-angiogenic cocktail. Nature. 416:2002;279-280.
148. Joensuu H., Roberts P.J., Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344:2001;1052-1056.
149. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:2000;95-105.
150. Furge K.A., Kiewlich D., Le P.et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10722-10727.
151. Norgaard P., Law B., Joseph H.et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. 5:1999;35-42.
152. Roumiantsev S., Shah N.P., Gorre M.E.et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. U.S.A. 99:2002;10700-10705.
153. Berman H.M., Westbrook J., Feng Z.et al. The protein data bank. Nucleic Acids Res. 28:2000;235-242.
154. Sayle R.A., Milner-White E.J. RASMOL: biomolecular graphics for all. Trends Biochem. Sci. 20:1995;374.
155. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone, in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277:2002;46265-46272.
156. Goetz M., Carlotti C., Bontems F., Dufourc E.J. Evidence for an alpha-helix → pi-bulge helicity modulation for the neu/erbB-2 membrane-spanning segment. A 1H NMR and circular dichroism study. Biochemistry. 40:2001;6534-6540.
157. Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature. 407:2000;1029-1034.
158. Mohammadi M., McMahon G., Sun L. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960.
159. Maignan S., Guilloteau J.P., Fromage N., Arnoux B., Becquart J., Ducruix A. Crystal structure of the mammalian Grb2 adaptor. Science. 268:1995;291-293.
160. Dhe-Paganon S., Ottinger E.A., Nolte R.T., Eck M.J., Shoelson S.E. Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1. Proc. Natl. Acad. Sci. U.S.A. 96:1999;8378-8383.
161. Siegal G., Davis B., Kristensen S.M.et al. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase. J. Mol. Biol. 276:1998;461-478.